BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 21307388)

  • 1. Challenges in the gynecologic care of premenopausal women with breast cancer.
    Bakkum-Gamez JN; Laughlin SK; Jensen JR; Akogyeram CO; Pruthi S
    Mayo Clin Proc; 2011 Mar; 86(3):229-40. PubMed ID: 21307388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Women's health, breast health: a review of the gynecologic effects of breast cancer.
    Goldman M; O'Hair K
    Obstet Gynecol Surv; 2009 Jul; 64(7):469-80; quiz 499. PubMed ID: 19545455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.
    Lee M; Piao J; Jeon MJ
    Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
    Bui KT; Willson ML; Goel S; Beith J; Goodwin A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Dominick S; Hickey M; Chin J; Su HI
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.
    Nourmoussavi M; Pansegrau G; Popesku J; Hammond GL; Kwon JS; Carey MS
    Cancer Treat Rev; 2017 Apr; 55():26-35. PubMed ID: 28288389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Romero SA; Young K; Hickey M; Su HI
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonorgestrel Intrauterine Device Placement in a Premenopausal Breast Cancer Patient with a Bicornuate Uterus.
    Eskew AM; Crane EK
    J Minim Invasive Gynecol; 2016 Jan; 23(1):133-5. PubMed ID: 26342448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
    Cheng WF; Lin HH; Torng PL; Huang SC
    Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
    Chalas E; Costantino JP; Wickerham DL; Wolmark N; Lewis GC; Bergman C; Runowicz CD
    Am J Obstet Gynecol; 2005 Apr; 192(4):1230-7; discussion 1237-9. PubMed ID: 15846210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
    Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
    Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
    Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
    J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.
    Hong J; Huang J; Shen L; Zhu S; Gao W; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    BMC Cancer; 2020 Jul; 20(1):663. PubMed ID: 32677982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gynecologic monitoring of tamoxifen treatment of breast cancer].
    Le Bouedec G; Pingeon JM; Fondrinier E; Kauffmann P; Dauplat J
    Rev Fr Gynecol Obstet; 1995; 90(7-9):379-82. PubMed ID: 7481445
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women.
    Chan SS; Tam WH; Yeo W; Yu MM; Ng DP; Wong AW; Kwan WH; Yuen PM
    BJOG; 2007 Dec; 114(12):1510-5. PubMed ID: 17995495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Emens LA; Davidson NE
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.